Current Takeaway
Hyperbaric Oxygen Therapy (HBOT) is an intervention that involves breathing pure oxygen in a pressurized chamber, which increases blood oxygenation and tissue perfusion. In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia, and Long COVID, clinical trials, prospective registries, and neuroimaging studies explore whether HBOT can alleviate core symptoms like fatigue, chronic pain, and cognitive dysfunction. The scientific rationale for HBOT centers on its potential to reverse tissue hypoxia, reduce neuroinflammation, and restore functional brain connectivity.
Recent research has advanced the field by providing both larger real-world registry data and objective neuroimaging correlates. A systematic review in fibromyalgia confirmed pain-relief benefits from early trials, while a large-scale Long COVID registry reported quality-of-life improvements in about 60% of patients. Most recently, a prospective cohort study in ME/CFS linked clinical improvements to the normalization of baseline thalamic functional hyperconnectivity using fMRI, suggesting a specific central nervous system mechanism.
However, the state of the evidence remains early and characterized by significant uncertainty. All major clinical findings are derived from systematic reviews of small trials, uncontrolled registries, or small prospective cohorts without a sham-control group. Because intensive daily protocols can be physically exhausting, there is a documented risk of clinical deterioration in a subset of patients, particularly those prone to post-exertional malaise (PEM). Large-scale, randomized, double-blind sham-controlled trials are urgently needed to establish true efficacy and standardized, safe protocols.
Why This Matters
HBOT is a highly sought-after, expensive, and intensive intervention that is currently being accessed off-label by patients. Understanding the research helps balance potential clinical benefits—such as cognitive improvement and physical functional gains—against real-world safety signals of clinical worsening, which is particularly hazardous for patients with post-exertional malaise (PEM). Furthermore, functional MRI (fMRI) data provides a measurable biological marker (thalamic connectivity) that links patient-reported improvements to objective brain changes, moving the clinical conversation beyond subjective questionnaires.
State of Evidence
- Established: Standard daily HBOT protocols carry a high patient burden, and mild barotrauma (ear pressure issues) is the most common reversible side effect across clinical cohorts.
- Plausible but early: HBOT may improve pain, fatigue, and cognitive function in fibromyalgia, Long COVID, and ME/CFS; a 40-session protocol appears superior to 20 sessions for physical functional gains and pain relief; clinical response is associated with fMRI normalization of baseline thalamic hyperconnectivity.
- Not established: True clinical efficacy of HBOT (differentiating active treatment from sham/placebo effects) in post-infectious cohorts; long-term durability of clinical benefit beyond 11 months.
- Key limitations: Most clinical studies are small, observational, and lack a sham-treatment control group, which is crucial due to high placebo susceptibility; prospective registries and off-label access exhibit selection bias due to self-funding; demanding protocols can trigger post-exertional malaise (PEM) or clinical worsening; severely affected, homebound patients are excluded from trial designs, limiting generalizability.
Timeline
2023-01-23 - Systematic review and meta-analysis support HBOT efficacy in fibromyalgia
A systematic review and meta-analysis of nine clinical trials (288 total patients) reported that hyperbaric oxygen therapy (HBOT) significantly relieved pain and improved other core symptoms, including fatigue, sleep, and overall function, in patients with fibromyalgia. This update consolidates early clinical evidence from both randomized and non-randomized trials, suggesting that HBOT could be a promising non-invasive option for fibromyalgia, a condition with high symptomatic overlap with ME/CFS and Long COVID. However, because the meta-analysis was based on a small number of randomized controlled trials with varied protocols (pressure levels and durations), it does not establish standardized treatment guidelines. Additionally, the review noted that 23.8% of patients experienced mild, reversible ear pressure issues (barotrauma) and 6.5% withdrew due to side effects, suggesting that lower-pressure protocols (under 2.0 ATA) may be necessary to improve safety and tolerability.
Sources:
2025-08-04 - Real-world Long COVID registry reports mixed outcomes and worsening in a minority
A prospective observational registry tracking 232 Long COVID patients across six Dutch hyperbaric centers found that 3 months after HBOT, 56–63% of patients experienced clinically relevant improvements in cognitive symptoms and quality of life, but 13–19% suffered significant clinical deterioration. This finding provides the first large-scale, real-world cohort data and highlights a critical safety signal: the intensive, demanding protocol of daily HBOT sessions can be exhausting and may trigger clinical worsening, potentially by inducing post-exertional malaise (PEM). However, the study’s observational design lacks a placebo or sham control group, meaning it cannot prove that the reported benefits were caused directly by the HBOT itself. Furthermore, it does not prove the treatment helps patients return to work (with only 11% of unable-to-work patients resuming work) and contains selection bias, as the off-label therapy had to be entirely self-funded by patients.
Sources:
2026-06-05 - Peer-reviewed prospective study and clinical updates link HBOT outcomes to brain connectivity and dose
A prospective cohort study of 30 ME/CFS patients undergoing 40 HBOT sessions (90-minute sessions at 2.0 ATA and 100% oxygen, 3–5 times weekly) demonstrated significant improvements in physical function, pain, fatigue, exercise capacity, and information processing speed, which correlated with the normalization of baseline thalamic functional hyperconnectivity on fMRI. At the ME/CFS Symposium 2026, Dr. Claudia Kedor presented comparative results from this trial cohort showing that the 40-session protocol was superior to a shorter 20-session course, which failed to show sustained improvements in pain, muscle strength, or physical capacity. Clinical responders (exhibiting a ≥10-point improvement on the SF-36 physical functioning scale) experienced sustained symptomatic benefits lasting up to 11 months post-treatment. However, because the study design was open-label and lacked a sham-control group, it cannot prove direct clinical efficacy. Additionally, the trial excluded severely ill, homebound patients, meaning these results and safety profiles cannot be generalized to the most vulnerable patient populations.
Sources:
2026-06-18 - Pilot study evaluates community-delivered lower-pressure HBOT (1.4 ATA) for Long COVID
A mixed-methods pilot study of six participants with Long COVID evaluated the safety and feasibility of community-delivered hyperbaric oxygen therapy (HBOT) using a single-person chamber at 1.4 ATA in a community pharmacy. Following a 4-week treatment course, participants reported short-term improvements in fatigue, breathlessness (dyspnea), and overall quality of life. The lower-pressure protocol was safe and well-tolerated, and delivering the therapy in a community setting successfully increased accessibility. However, participants noted that traveling to and attending regular, frequent sessions was physically and logistically challenging due to their chronic illness. Due to the extremely small sample size and lack of a control group, larger randomized sham-controlled trials are required to establish efficacy and define optimal treatment protocols.
Sources: